<--- Back to Details
First PageDocument Content
Biology / Neurodegenerative disorders / Niemann–Pick disease / Medicine / Sphingomyelin phosphodiesterase 1 / Lysosomal storage disease / Epididymal secretory protein E1 / NPC1 / Genetic disorder / Lipid storage disorders / Rare diseases / Health
Date: 2012-01-11 14:43:10
Biology
Neurodegenerative disorders
Niemann–Pick disease
Medicine
Sphingomyelin phosphodiesterase 1
Lysosomal storage disease
Epididymal secretory protein E1
NPC1
Genetic disorder
Lipid storage disorders
Rare diseases
Health

experience a e National Niemann-Pick Disease Foundation PERSEVERE

Add to Reading List

Source URL: www.nnpdf.org

Download Document from Source Website

File Size: 755,41 KB

Share Document on Facebook

Similar Documents

Product Datasheet  Anti-Acid sphingomyelinase antibody [mAbcam74281] ab74281 1 Abreviews

Product Datasheet Anti-Acid sphingomyelinase antibody [mAbcam74281] ab74281 1 Abreviews

DocID: QysL - View Document

National Niemann-Pick Disease Foundation Grant #48 Six-Month Progress: Lay Summary – Edward H. Schuchman, PhD The goal of our research is to create a new mouse model of Type A NPD. This mouse will make an abnormal (or

National Niemann-Pick Disease Foundation Grant #48 Six-Month Progress: Lay Summary – Edward H. Schuchman, PhD The goal of our research is to create a new mouse model of Type A NPD. This mouse will make an abnormal (or

DocID: AXwj - View Document

Membrane biology / Phospholipids / Sphingomyelin / Niemann–Pick disease / Lysosome / Lysosomal storage disease / Niemann-Pick disease /  SMPD1-associated / Sphingomyelin phosphodiesterase 1 / Biology / Lipid storage disorders / Rare diseases

National Niemann-Pick Disease Foundation Grant #48 Six-Month Progress: Lay Summary – Edward H. Schuchman, PhD The goal of our research is to create a new mouse model of Type A NPD. This mouse will make an abnormal (or

DocID: AKti - View Document

Update from Genzyme on Acid Sphingomyelinase Deficiency (ASMD) Clinical Trials November 15, 2012 Genzyme, a Sanofi company, is continuing efforts to develop recombinant human acid sphingomyelinase (rhASM) for the potenti

Update from Genzyme on Acid Sphingomyelinase Deficiency (ASMD) Clinical Trials November 15, 2012 Genzyme, a Sanofi company, is continuing efforts to develop recombinant human acid sphingomyelinase (rhASM) for the potenti

DocID: zprx - View Document

experience a  e National Niemann-Pick Disease Foundation  PERSEVERE

experience a e National Niemann-Pick Disease Foundation PERSEVERE

DocID: xHuD - View Document